Arena Pharmaceuticals to Present Corporate Update at the Rodman & Renshaw Techvest Global Healthcare Conference
SAN DIEGO, May 6 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today that Dominic Behan, Vice President, Research
and co-founder of Arena, is scheduled to present a corporate update at the
Rodman & Renshaw Techvest Global Healthcare Conference on Wednesday,
May 12, 2004. The presentation is scheduled to take place at 1:00 PM London
Time (5:00 AM Pacific Time and 8:00 AM Eastern Time) at the Claridge's Hotel
To access the live audio broadcast or the subsequent archived recording,
log on to http://www.arenapharm.com and go to the investor relations section.
Please connect to Arena's website several minutes prior to the start of the
conference call to ensure adequate time for any software download that may be
Arena is a biopharmaceutical company focusing on the discovery,
development and commercialization of drugs in four major therapeutic areas:
metabolic, cardiovascular, central nervous system and inflammatory diseases.
Arena is developing a broad pipeline of compounds including one in Phase 1
clinical trials for obesity and another in preclinical development for
insomnia. The company's compounds act on an important class of drug targets
called G protein-coupled receptors, or GPCRs, and were developed using Arena's
proprietary technologies, including CART (Constitutively Activated
Receptor Technology) and Melanophore. Arena also has research collaborations
with Merck, Fujisawa, Taisho and TaiGen for products in a number of different
indications. For additional information about Arena, please visit their
website at http://www.arenapharm.com.
Contact: Jack Lief Susan Neath
Arena Pharmaceuticals Atkins + Associates
858-453-7200, ext. 223 858-527-3486
SOURCE Arena Pharmaceuticals, Inc.
CONTACT: Jack Lief of Arena Pharmaceuticals, +1-858-453-7200, ext. 223
or Susan Neath of Atkins Associates, +1-858-527-3486 for Arena
Web site: http://www.arenapharm.com